Effect of Canagliflozin on Blood Pressure and Adverse Events Related to Osmotic Diuresis and Reduced Intravascular Volume in Patients With Type 2 Diabetes Mellitus
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
The effects of canagliflozin, a sodium glucose co‐transporter 2 inhibitor, on blood pressure (BP) and osmotic diuresis– and intravascular volume reduction–related adverse events (AE s) were evaluated using pooled data from four placebo‐controlled, phase 3 studies in patients with type 2 diabetes mellitus (T2 DM; N=2313). At baseline, 1332 (57.6%) patients were taking an antihypertensive medication. Canagliflozin 100 mg and 300 mg provided reductions (95% confidence interval [CI]) from baseline in systolic BP (SBP) compared with placebo (−4.3 mm Hg [−5.0 to −3.5], −5.0 mm Hg [−5.8 to −4.2], and −0.3 mm Hg [−1.2 to 0.5], respectively) and in diastolic BP (DBP; −2.5 mm Hg [−2.9 to −2.0], −2.4 mm Hg [−2.9 to −1.9], and −0.6 mm Hg [−1.1 to −0.02], respectively). Placebo‐subtracted reductions (95% CI) in SBP with canagliflozin 100 mg and 300 mg were −4.0 mm Hg (−5.1 to −2.8) and −4.7 mm Hg (−5.8 to −3.5) and reductions in DBP were −1.9 mm Hg (−2.6 to −1.2) and −1.9 mm Hg (−2.6 to –1.1), respectively. Compared with the overall population, patients with elevated baseline SBP (≥140 mm Hg) had numerically greater absolute SBP reductions (95% CI) with canagliflozin 100 mg and 300 mg and placebo (−12.8 mm Hg [−15.2 to −10.5], −14.2 mm Hg [−16.4 to −12.0], and −6.8 mm Hg [−9.1 to −4.5], respectively). Numerically greater DBP reductions were seen in patients with DBP ≥90 mm Hg at baseline (−5.9 mm Hg [−8.2 to −3.6], −9.0 mm Hg [−11.1 to −6.9], and −7.4 mm Hg [−9.6 to −5.1], respectively). In patients with elevated SBP at baseline, placebo‐subtracted reductions (95% CI) in SBP with canagliflozin 100 mg and 300 mg were −6.0 mm Hg (−9.1 to −2.9) and −7.4 mm Hg (−10.4 to −4.4), respectively. Placebo‐subtracted changes in DBP were 1.5 mm Hg (−1.6 to 4.5) and −1.6 mm Hg (−4.5 to 1.2), respectively, in those with elevated DBP at baseline. Canagliflozin 100 mg and 300 mg were associated with increased incidence of osmotic diuresis–related AE s (eg, pollakiuria [increased urine volume] and polyuria [increased urine frequency]) vs placebo (6.7%, 5.6%, and 0.8%). The incidence of intravascular volume reduction–related AE s (eg, orthostatic hypotension and postural dizziness) was low across groups (1.2%, 1.3%, and 1.1%). In summary, canagliflozin was associated with reduced BP in patients with T2 DM across a range of baseline BPs, with increased incidence of AE s related to osmotic diuresis but not intravascular volume reduction.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Standards of medical care in diabetes—2013
American Diabetes Association (2013) · Diabetes Care · doi:10.2337/dc13-s011 · Cited by 4,369
Sha, S., Polidori, D., Heise, T., Natarajan, J., Farrell, K., Wang, S. ‐., Sica, D., Rothenberg, P., & Plum‐Mörschel, L. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12322 · Cited by 249
Cited by
Proximal Tubulopathy: Prime Mover and Key Therapeutic Target in Diabetic Kidney Disease
Gilbert, R. E. (2017) · Diabetes · doi:10.2337/db16-0796 · Cited by 362
Self-citationPacker, M., Anker, S. D., Butler, J., Filippatos, G., & Zannad, F. (2017) · JAMA Cardiology · doi:10.1001/jamacardio.2017.2275 · Cited by 336
Effect of SGLT2 Inhibitors on the Sympathetic Nervous System and Blood Pressure
Scheen, A. J. (2019) · Current Cardiology Reports · doi:10.1007/s11886-019-1165-1 · Cited by 122
Townsend, R. R., Machin, I., Ren, J., Trujillo, A., Kawaguchi, M., Vijapurkar, U., Damaraju, C. V., & Pfeifer, M. (2016) · The Journal of Clinical Hypertension · doi:10.1111/jch.12747 · Cited by 85
“It should be noted that this study was not designed and powered to evaluate the attainment of the guideline-based BP goal; however, a large pooled data analysis showed that canagliflozin treatment led a greater proportion of patients to achieve their BP goal compared with placebo.(6) The use of ABPM also avoids the “w…”
BackgroundResultInfluentialSelf-citationImprialos, K. P., Sarafidis, P. A., & Karagiannis, A. I. (2015) · Journal of Hypertension · doi:10.1097/hjh.0000000000000719 · Cited by 71
Cardiometabolic effects of a new class of antidiabetic agents
Desouza, C. V., Gupta, N., & Patel, A. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.02.016 · Cited by 54
Muzurović, E., & Mikhailidis, D. P. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1795132 · Cited by 35
Metadata
- Authors
- Weir, M. R., Januszewicz, A., Gilbert, R. E., Vijapurkar, U., Kline, I., Fung, A., & Meininger, G.
- Venue
- The Journal of Clinical Hypertension
- Publisher
- Wiley
- Published
- 2014-10-20
- Volume
- 16
- Issue
- 12
- Pages
- 875-882
- ISSN
- 1524-6175 (ISSN-L)
- 1751-7176
- OpenAlex
- W1981671332
- Cited by
- 120
- References
- 2
- FWCI
- 11.25
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.